Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 10:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 1,493 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Patch 2 Clear all
Recruiting Phase 4 Interventional

Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions

NCT03014687
View directory record Official record
Conditions
Antibiotics, Pituitary Adenoma
Interventions
Placebo, Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 84 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 26, 2026, 10:52 PM EDT
Completed Phase 3 Interventional Results available

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline

NCT00506415
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Rivastigmine 5 cm^2, Rivastigmine 10 cm^2, Rivastigmine 15 cm^2, Placebo to 15 cm^2 patch, Placebo to 10 cm^2 patch
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 85 Years
Enrollment
1,584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
65
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Oct 26, 2026, 10:52 PM EDT
Completed Not applicable Interventional Results available

Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer

NCT03035890
View directory record Official record
Conditions
Non Small Cell Lung Cancer Metastatic
Interventions
Radiation, Immuno-Therapeutic Agent
Radiation · Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 26, 2026, 10:52 PM EDT
Completed Phase 3 Interventional Results available

Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease

NCT00428389
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rivastigmine 5 cm^2 transdermal patch, Rivastigmine 10 cm^2 transdermal patch
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
23
States / cities
Sun City, Arizona • Costa Mesa, California • Fresno, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 26, 2026, 10:52 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia

NCT05660525
View directory record Official record
Conditions
Smoking Cessation, Smoking, Cigarette, Smoking Reduction, Smoking, Smoking, Tobacco, Quitting Smoking
Interventions
4 weeks of Nicotine lozenge, 8 weeks of Nicotine Replacement Therapy Patch, QuitAid, Smokefree TXT, Tobacco Quitline, 4 weeks of Nicotine Replacement Therapy Patch, 8 Weeks Nicotine Lozenge
Drug · Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
768 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 26, 2026, 10:52 PM EDT
Completed Not applicable Interventional

Innovations to Prevent Relapse Among Low-income African American Smokers

NCT03982576
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nicotine replacement therapy (NRT), CS-CBT intervention, Path2Quit, Relapse prevention program, SmokefreeTXT
Other · Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 26, 2026, 10:52 PM EDT
Withdrawn Phase 3 Interventional

Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp

NCT03024060
View directory record Official record
Conditions
Actinic Keratosis
Interventions
ALA, Vehicle, IBL 20 mW, IBL 10 mW
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
San Diego, California • Arlington Heights, Illinois • Carmel, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 26, 2026, 10:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

KEEPS Mammographic Density And Breast Health Ancillary Study

NCT02524561
View directory record Official record
Conditions
Mammographic Density, Abnormal Mammogram
Interventions
CEE pill, Estradiol patch, Active Progesterone, Placebo tablet, Placebo patch, Placebo progesterone
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
42 Years to 58 Years · Female only
Enrollment
517 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 26, 2026, 10:52 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

NCT04262154
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Atezolizumab, Abiraterone, Prednisone, GnRH analog, Stereotactic Body Radiotherapy (SBRT), Enzalutamide, Follow up
Drug · Radiation · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 26, 2026, 10:52 PM EDT
Completed Phase 2 Interventional Results available

Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma

NCT04796194
View directory record Official record
Conditions
Advanced Melanoma
Interventions
LTX-315 in combination with pembrolizumab
Combination Product
Lead sponsor
Lytix Biopharma AS
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
New York, New York • Charlotte, North Carolina • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 26, 2026, 10:52 PM EDT
Completed Phase 3 Interventional

Etodolac-Lidocaine Patch in the Treatment of Acute Low Back Pain

NCT01968005
View directory record Official record
Conditions
Low Back Pain
Interventions
Etoreat®(Etodolac-Lidocaine Topical Patch), Placebo
Drug
Lead sponsor
MEDRx USA, Inc.
Industry
Eligibility
14 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Carlsbad, California • Miami, Florida • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 26, 2026, 10:52 PM EDT
Completed Phase 4 Interventional

Dissemination of Tobacco Tactics for Hospitalized Smokers

NCT01309217
View directory record Official record
Conditions
Smoking Cessation
Interventions
Tobacco Tactics Intervention, Usual Care
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1,528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Grand Rapids, Michigan • Livonia, Michigan • Muskegon, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 26, 2026, 10:52 PM EDT
Recruiting Phase 1Phase 2 Interventional

Amiodarone-Infused CardiaMend Patches for the Prevention of New-Onset POAF in Cardiac Surgery Subjects

NCT06730828
View directory record Official record
Conditions
Atrial Fibrillation, Postoperative
Interventions
The intervention includes Amiodarone-Infused CardiaMend patches (70mg, 150mg and 300mg)
Combination Product
Lead sponsor
Helios Cardio Inc.
Industry
Eligibility
20 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 26, 2026, 10:52 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Genetically Informed Smoking Cessation Trial

NCT02351167
View directory record Official record
Conditions
Smoking Cessation
Interventions
Combination NRT (Nicotine patch, Nicotine lozenge), Varenicline, Placebo, Intensive smoking counseling
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years and older
Enrollment
822 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 26, 2026, 10:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Tetrix on Alleviation of Burning,Itching Associated With Lesions of Contact Dermatitis

NCT00646867
View directory record Official record
Conditions
Contact Dermatitis
Interventions
Tetrix, Placebo
Device
Lead sponsor
Coria Laboratories, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 22, 2008 · Synced Oct 26, 2026, 10:52 PM EDT
Completed Phase 3 Interventional Results available

Telephone Counseling and the Distribution of Nicotine Patches to Smokers

NCT00851357
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nicotine Patch, Telephone Counseling, Placebo, Self-Help Materials
Drug · Behavioral · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
4,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Oct 26, 2026, 10:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)

NCT00890565
View directory record Official record
Conditions
Healthy
Interventions
granisetron
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Oct 26, 2026, 10:52 PM EDT
Completed Not applicable Interventional Results available

Smoking Cessation Using Motivational Therapy and Varenicline

NCT00701896
View directory record Official record
Conditions
Smoking, HIV Infections
Interventions
Varenicline tartrate, Nicotine Replacement Therapy, Biological Control, Motivational Interview
Drug · Other · Behavioral
Lead sponsor
Philip Diaz
Other
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 26, 2026, 10:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lutronic LaseMD for Treatment of Benign Pigmented Lesions

NCT03409952
View directory record Official record
Conditions
Benign Pigmented Lesions
Interventions
LaseMD and DUAL 1927nm Laser, LaseMD
Device
Lead sponsor
CynosureLutronic
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Hunt Valley, Maryland • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 26, 2026, 10:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Contingency Management, Quitting Smoking, and ADHD

NCT02266784
View directory record Official record
Conditions
Cigarette Smoking, Smoking Cessation
Interventions
Contingency Management (CM), Transdermal nicotine skin patches (i.e. Habitrol), Supportive Counseling
Behavioral · Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 26, 2026, 10:52 PM EDT
Completed Phase 2 Interventional Results available

New Technologies to Determine Carotid Plaque Vulnerability in Patients With Significant Carotid Plaques

NCT03335033
View directory record Official record
Conditions
Carotid Artery Plaque
Interventions
Contrast-enhanced ultrasound, Shear Wave Elastography, Ultrasound Examination
Combination Product · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 26, 2026, 10:52 PM EDT
Active, not recruiting Early Phase 1 Interventional

Intralesional Cyclosporine for Alopecia Areata

NCT07029204
View directory record Official record
Conditions
Alopecia Areata
Interventions
CycloSPORINE Injectable Product, Saline Solution
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 26, 2026, 10:52 PM EDT
Completed Phase 1 Interventional

Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment

NCT00544284
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, temozolomide, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 26, 2026, 10:52 PM EDT
Active, not recruiting Not applicable Interventional

Robotic Versus Electromagnetic Bronchoscopy for Pulmonary LesIon AssessmeNT Using Integrated Intraprocedural Imaging

NCT06654271
View directory record Official record
Conditions
Peripheral Pulmonary Lesion, Lung Nodule, Solitary
Interventions
Robotic assisted bronchoscopy (RAB), Electromagnetic navigation bronchoscopy (ENB)
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 26, 2026, 10:52 PM EDT